etodolac has been researched along with Cell Transformation, Neoplastic in 3 studies
Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).
etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.
Cell Transformation, Neoplastic: Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
| Excerpt | Relevance | Reference |
|---|---|---|
| "iii) Treatment with etodolac alone." | 5.35 | Inhibitory effects of the cyclooxygenase-2 inhibitor, etodolac, on colitis-associated tumorigenesis in p53-deficient mice treated with dextran sulfate sodium. ( Abe, A; Fujii, S; Fujimori, T; Fukui, H; Hiraishi, H; Ichikawa, K; Imura, J; Kono, T; Mukawa, K; Ono, Y; Sekikawa, A; Shinoda, M; Tominaga, K; Tomita, S; Yoshitake, N, 2008) |
| "iii) Treatment with etodolac alone." | 1.35 | Inhibitory effects of the cyclooxygenase-2 inhibitor, etodolac, on colitis-associated tumorigenesis in p53-deficient mice treated with dextran sulfate sodium. ( Abe, A; Fujii, S; Fujimori, T; Fukui, H; Hiraishi, H; Ichikawa, K; Imura, J; Kono, T; Mukawa, K; Ono, Y; Sekikawa, A; Shinoda, M; Tominaga, K; Tomita, S; Yoshitake, N, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kapadia, GJ | 1 |
| Azuine, MA | 1 |
| Shigeta, Y | 1 |
| Suzuki, N | 1 |
| Tokuda, H | 1 |
| Yamamoto, K | 1 |
| Kitayama, W | 1 |
| Denda, A | 1 |
| Sasahira, T | 1 |
| Kuniyasu, H | 1 |
| Kirita, T | 1 |
| Mukawa, K | 1 |
| Fujii, S | 1 |
| Tominaga, K | 1 |
| Yoshitake, N | 1 |
| Abe, A | 1 |
| Kono, T | 1 |
| Sekikawa, A | 1 |
| Fukui, H | 1 |
| Ichikawa, K | 1 |
| Tomita, S | 1 |
| Imura, J | 1 |
| Ono, Y | 1 |
| Shinoda, M | 1 |
| Hiraishi, H | 1 |
| Fujimori, T | 1 |
3 other studies available for etodolac and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
Chemopreventive activities of etodolac and oxyphenbutazone against mouse skin carcinogenesis.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anticarcinogenic Agents; Carcinogens; Cell Transformation | 2010 |
Expression of receptor for advanced glycation end products during rat tongue carcinogenesis by 4-nitroquinoline 1-oxide and effect of a selective cyclooxygenase-2 inhibitor, etodolac.
Topics: 4-Nitroquinoline-1-oxide; Animals; Anticarcinogenic Agents; Cell Transformation, Neoplastic; Cycloox | 2006 |
Inhibitory effects of the cyclooxygenase-2 inhibitor, etodolac, on colitis-associated tumorigenesis in p53-deficient mice treated with dextran sulfate sodium.
Topics: Animals; Cell Transformation, Neoplastic; Chemoprevention; Colitis; Colonic Neoplasms; Cyclooxygenas | 2008 |